$20M series A round for Civitas breathes life into Alkermes' inhaled drug delivery
This article was originally published in Scrip
Executive Summary
Civitas Therapeutics, a new company spun out of Alkermes' pulmonary delivery business, has secured $20 million of series A financing from founding investor Longitude Capital, along with co-lead Canaan Partners.